Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef

Blood (2024) 144 (Supplement 1): 7614.

https://doi.org/10.1182/blood-2024-207898

Published: 2024

Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2024-203994

Published: 2024

Journal Articles

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Kim Linton, John N. Allan, Andrew S Park, Anthony W Wang, Summer Tran, Alex Mutebi, Zhijie Ding, Quan Chen, Tycel J. Phillips

Blood (2024) 144 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2024-200989

Published: 2024

Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Karen Cumings, Viktor Chirikov, Zhijie Ding, Felipe Marques Goncalves, Nicole Heaps, Savreet Bains Chawla, Anthony W Wang, Mohammad Atiya, Fernando Rivas Navarro, Elena Favaro, Daniela Hoehn, Alex Mutebi

Blood (2024) 144 (Supplement 1): 7802.

https://doi.org/10.1182/blood-2024-200799

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2024-203876

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2024-203540

Published: 2024

Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont

Blood (2023) 142 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2023-180047

Published: 2023

Journal Articles

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Blood (2023) 142 (Supplement 1): 309.

https://doi.org/10.1182/blood-2023-174497

Published: 2023

Journal Articles

Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma

Tycel Philips, Laurie H. Sehn, Anthony Wang, Junhua Yu, Elizabeth H. Marchlewicz, Rajesh Kamalakar, Kavita Sail, Donald Arnette, Shibing Yang, Alex Mutebi, Fernando Rivas Navarro, Gilles Salles

Blood (2023) 142 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2023-180088

Published: 2023

Journal Articles

Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony Wang

Blood (2023) 142 (Supplement 1): 5089.

https://doi.org/10.1182/blood-2023-181177

Published: 2023

Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont

Blood (2022) 140 (Supplement 1): 8022–8023.

https://doi.org/10.1182/blood-2022-159544

Published: 2022

Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov

Blood (2022) 140 (Supplement 1): 10934–10935.

https://doi.org/10.1182/blood-2022-158028

Published: 2022

Journal Articles

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Tycel Phillips, Junhua Yu, Rajesh Kamalakar, Kalatu R. Davies, Alex Mutebi, Savreet Bains Chawla, Donald Arnette, Syed Quadri, Anthony Wang

Blood (2022) 140 (Supplement 1): 5241–5243.

https://doi.org/10.1182/blood-2022-157773

Published: 2022

Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott

Blood (2022) 140 (Supplement 1): 6693–6694.

https://doi.org/10.1182/blood-2022-159569

Published: 2022

Journal Articles

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Kalatu R. Davies, Rajesh Kamalakar, Junhua Yu, Yinan Huang, Anthony Wang, Kavita Sail, Thomas Doerr, Simon Sharmokh, Alex Mutebi, Gilles Salles

Blood (2022) 140 (Supplement 1): 5058–5059.

https://doi.org/10.1182/blood-2022-157758

Published: 2022

Journal Articles

Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees

Mufaddal Mahesri, MD MPH, Sebastian Schneeweiss, MD ScD, Raisa Levin, Denise Globe, PhD, Krista McKerracher, MBA, Alex Mutebi, PhD, Rhonda Bohn, ScD, Maureen Achebe, MD MPH, Rishi J Desai, MS, PhD

Blood (2019) 134 (Supplement_1): 2166.

https://doi.org/10.1182/blood-2019-130724

Published: 2019

Journal Articles

Clinical Outcomes and Healthcare Utilization in Patients with Sickle Cell Disease: A Nationwide Cohort Study of Medicaid Beneficiaries

Rishi J Desai, MS, PhD, Mufaddal Mahesri, MD MPH, Raisa Levin, Denise Globe, PhD, Krista McKerracher, MBA, Alex Mutebi, PhD, Rhonda Bohn, ScD, Maureen Achebe, MD MPH, Sebastian Schneeweiss, MD ScD

Blood (2019) 134 (Supplement_1): 3459.

https://doi.org/10.1182/blood-2019-130373

Published: 2019

NARROW

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma

Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Clinical Outcomes Following Bone Marrow Transplant in Patients with Sickle Cell Disease: A Cohort Study of US Medicaid Enrollees

Clinical Outcomes and Healthcare Utilization in Patients with Sickle Cell Disease: A Nationwide Cohort Study of Medicaid Beneficiaries

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only